A National Drug Code (NDC) is FDA’s three-segment identifier used in drug-listing records to identify the labeler, drug product, and commercial package. FDA currently assigns 10-digit NDCs. The labeler proposes the product and package segments under its FDA-assigned Labeler Code as part of the electronic drug-listing process. An NDC identifies a listed drug product; it does not mean FDA has approved, endorsed, certified, or verified that product.
FDA Registration Assistance handles NDC product and package code setup, SPL drug-listing preparation, FDA Direct submission support, and NDC Directory verification for prescription and OTC drug products subject to U.S. drug-listing requirements.
Under 21 CFR Part 207, drug establishments must register and drug products subject to listing requirements must be listed for U.S. commercial distribution. The NDC is the three-segment identifier used within that system to identify the labeler, product, and commercial package. FDA currently assigns 10-digit NDCs; the uniform 12-digit 6-4-2 FDA format begins March 7, 2033.
FDA Registration Assistance reviews the underlying Labeler Code, establishment, product, ingredient, package, and labeling records, then prepares the SPL drug listing and supports submission through FDA Direct. We also verify the published listing data after acceptance.
Everything drug companies need to obtain, assign, and file NDC codes correctly — from product code assignment to FDA drug listing, handled by experienced FDA compliance specialists.
We review the formulation, strength, dosage form, route of administration, and marketing category, then establish the product-code segment under your FDA Labeler Code.
We review each commercial package size and type and establish the package-code structure for the configurations included in your service scope.
We prepare the Structured Product Labeling drug-listing data required by FDA, including NDC, product, ingredient, establishment, package, and labeling information.
We support submission through FDA Direct and address filing, validation, or update issues that fall within the agreed service scope.
A quick view of the current FDA format, upcoming 2033 transition, and the professional fee for this service.
A simple four-step process to assign your NDC codes and file your SPL drug listing with the FDA.
Provide the Labeler Code, legal entity information, product formula, labeling, establishment details, and commercial package configurations.
We review the product structure, ingredient identifiers, marketing category, establishment records, and package information before building the listing.
We prepare the SPL drug listing and support submission through FDA Direct using the correct labeler and establishment records.
After acceptance, we verify the published NDC / listing data and identify any follow-up or future update obligations.
The NDC system is built on three layers of U.S. federal law that together establish the requirement to identify every commercially marketed drug product with a unique numeric code.
Section 510 of the Federal Food, Drug, and Cosmetic Act establishes drug-establishment registration and drug-listing obligations for covered operations and products. The NDC is used within FDA’s drug-listing system to identify listed drug products and packages.
View FD&C Act on FDA.gov21 CFR Part 207 governs drug establishment registration and drug listing, including Labeler Codes, NDC product/package segments, electronic SPL submissions, and required listing updates and certifications.
View 21 CFR Part 207 on eCFRFDA requires electronic drug registration and listing submissions in Structured Product Labeling format. FDA Direct provides a current web-based workflow for drug registration, Labeler Code requests, NDC reservations, and drug listings; other compliant SPL tools may transmit through FDA ESG NextGen.
View FDAAA on FDA.govFDA continues to assign 10-digit NDCs during the transition period through March 6, 2033. Beginning March 7, 2033, FDA will use a uniform 12-digit 6-4-2 format. Existing FDA-assigned 10-digit NDCs will be converted by FDA, while labeling and internal systems will need to transition on the agency's published timetable.
Read FDA's NDC format guidanceDrug listing is an ongoing compliance record. The labeler and registered establishments must keep the underlying information current, complete required updates or certifications, and avoid representing an NDC as FDA approval.
The product-code segment must distinguish the listed drug product under the labeler’s Labeler Code. Changes in formulation, strength, dosage form, or other product characteristics must be reviewed to determine whether a new product code is needed.
Commercial package configurations must be represented accurately. A new package size or type may require a new package code and an updated SPL listing.
The SPL must contain the required NDC, product, ingredient, establishment, marketing, package, and labeling information using the correct labeler records.
FDA expects drug-listing information to be updated as soon as possible after changes and, where periodic reporting is permitted, no later than the applicable June or December reporting period.
If no drug-listing information changed during the year, the required no-change certification is generally completed during October 1 through December 31. This is different from updating changed listing information.
Drug establishments subject to registration must maintain their annual FDA establishment registration, while the associated product listings must also remain current or properly certified.
An NDC or NDC Directory entry does not mean FDA approved, endorsed, certified, or verified the product. Marketing copy should never imply otherwise.
FDA currently assigns 10-digit NDCs. Many payer systems use an 11-digit 5-4-2 reimbursement conversion. FDA’s uniform 12-digit 6-4-2 format begins March 7, 2033.
These two FDA identifiers are routinely confused — but they identify completely different things. The Labeler Code identifies the company; the NDC identifies a specific product configuration.
| Attribute | NDC (National Drug Code) | Drug Labeler Code |
|---|---|---|
| Who Establishes It | The labeler proposes the Product Code and Package Code under its FDA-assigned Labeler Code as part of drug listing; FDA accepts and publishes the resulting NDC data. | FDA assigns the Labeler Code after an acceptable Labeler Code request. |
| What It Represents | A listed drug product and commercial package under the labeler’s code. | The labeler identified in the FDA drug-listing system. |
| Regulatory Context | Used in drug listing under FD&C Act §510 and 21 CFR Part 207. | Requested and maintained under 21 CFR Part 207 as the first NDC segment. |
| Governing Regulation | 21 CFR Part 207 (drug registration and listing) | 21 CFR 207.33 and related provisions |
| Primary Function | Identifies a listed drug product/package in FDA’s drug-listing records and is also used by many downstream pharmacy and reimbursement systems. | Identifies the labeler and supplies the first NDC segment. |
| Our Professional Fee | $199 USD per drug product | $349 USD per company |
The filings are sequential, not interchangeable. A company needs the correct FDA Labeler Code before the NDC product/package segments can be established and the drug listing completed. FDA currently assigns 10-digit NDCs and moves to the uniform 12-digit 6-4-2 format on March 7, 2033.
FDA Direct is available to industry users at no charge, but a compliant drug listing still requires accurate product, ingredient, establishment, package, labeling, and marketing-category data. Our professional fee covers the regulatory work and submission support around that filing.
| Factor | Self-Filing (DIY) | Recommended FDA Registration Assistance |
|---|---|---|
| Cost | $0 FDA government fee for the standard NDC / drug-listing submission itself, plus your internal staff time and any tools you use. | $199 USD professional service fee per drug product for NDC setup, SPL preparation, FDA Direct submission support, and verification within scope. |
| Submission Monitoring | You monitor acknowledgments, validation messages, and any needed corrections yourself. | We monitor the filing status and address submission issues within the agreed scope. |
| Drug-Listing Data | You are responsible for product/package structure, ingredient identifiers, marketing-category data, establishment information, and labeling. | We review and prepare the listing data from the records you provide before submission. |
| Validation Risk | Incomplete or inconsistent data can delay acceptance or require correction. | We perform a pre-submission review intended to identify common data and consistency issues before filing. |
| Verification | You verify the published NDC / drug-listing data yourself. | We verify the NDC / listing data after acceptance and flag any follow-up needed. |
| Updates | You track required product changes, periodic updates, and annual no-change certification when applicable. | We can assist with later SPL amendments, listing updates, and certification support as a separate or continuing scope. |
FDA does not charge a separate government fee simply to assign an NDC or submit a standard drug listing. The $199 amount shown on this page is FDA Registration Assistance’s professional service fee, not an FDA fee.
A quick reference of the technical acronyms, codes, and submission systems used throughout the NDC assignment and SPL drug listing process.
FDA’s three-segment identifier used in drug-listing records. FDA currently assigns 10-digit NDCs; the uniform 12-digit 6-4-2 format takes effect March 7, 2033.
The FDA-assigned first segment of the NDC. It identifies the labeler in FDA’s drug registration and listing system.
The second NDC segment, proposed by the labeler under its Labeler Code to distinguish a specific drug product.
The third NDC segment, proposed by the labeler to distinguish a commercial package configuration for the listed product.
The XML-based electronic format FDA uses for drug registration and listing submissions, including product, ingredient, establishment, package, and labeling data.
FDA’s free web-based SPL authoring and submission environment for drug establishment registration, drug listing, Labeler Code requests, NDC reservations, and related drug functions.
FDA’s electronic submission gateway used to transmit many compliant SPL submissions created outside FDA Direct or FDA’s SPL Xforms tools.
FDA’s public directory populated from drug-listing SPL data and updated daily. Directory inclusion reflects submitted listing information; it is not FDA approval.
FDA currently assigns 10-digit NDCs. Many reimbursement systems use an 11-digit 5-4-2 conversion. FDA’s uniform 12-digit 6-4-2 NDC format begins March 7, 2033.
The regulatory pathway declared in every SPL — NDA, ANDA, BLA, OTC monograph, unapproved drug, or compounded. The marketing category controls how the NDC is treated in FDA databases and pharmacy systems.
Unique Ingredient Identifier — a non-proprietary FDA code assigned to every drug substance and inactive ingredient. UNIIs are required in every SPL drug listing for both actives and excipients.
A business identifier used in FDA registration and listing workflows to help identify and align company and establishment records. The underlying legal name and address should remain consistent across regulatory records.
These are common data, filing, and maintenance issues that can delay acceptance, require correction, or cause a listing to become inactive. We review them before submission and during follow-up.
If the Labeler Code, legal entity, or related company records do not align with the filing, the drug listing may require correction before it can be completed accurately.
Drug listings must identify the appropriate marketing category and related application or monograph information when applicable. Incorrect or incomplete data can delay or prevent acceptance.
SPL drug listings require structured ingredient information. Missing or incorrect identifiers, strengths, or ingredient data can trigger validation or data-quality problems.
Product and package segments must accurately distinguish the listed product and commercial configurations. Reusing or structuring segments incorrectly can require correction and a revised SPL.
If no drug-listing information changed during the year, the required no-change certification is generally completed during October 1 through December 31. Listings that require certification but are not certified can become inactive in FDA publications.
The product labeling and SPL listing should remain consistent. Differences in product name, strength, dosage form, package information, or other listed data can create regulatory and downstream data problems.
FDA currently assigns 10-digit NDCs, while many reimbursement systems use an 11-digit 5-4-2 conversion. A billing-format error can create payer problems even when the FDA-assigned NDC itself is correct.
Drug establishments subject to registration must renew annually, and drug listings must be updated or certified as required. Inactive underlying records can affect the status and usefulness of the associated listing data.
These are the core filings most commonly needed before or alongside NDC / drug listing work. We keep this section limited to directly related drug-registration services.
Register and maintain the drug manufacturing, repacking, or relabeling establishment record — $449/year professional service fee.
Obtain the FDA Labeler Code needed before NDC product/package segments can be established — $349 professional service fee.
Obtain or resolve the DUNS information used to align FDA drug registration and listing records — $399 professional service fee.
U.S. Agent representation for foreign drug establishments that must designate a U.S. contact with FDA — $449/year professional service fee.
Direct answers about NDC format, Labeler Codes, SPL drug listings, professional fees, update timing, foreign companies, and NDC Directory verification.
A National Drug Code (NDC) is FDA’s three-segment identifier used in drug-listing records to identify the labeler, drug product, and commercial package. FDA currently assigns 10-digit NDCs. The product and package segments are proposed under the FDA-assigned Labeler Code as part of the drug-listing process.
No. An NDC identifies a listed drug product; it does not mean FDA has approved, endorsed, certified, or verified the product. FDA specifically warns that NDC assignment or inclusion in the NDC Directory should not be represented as FDA approval.
FDA currently assigns 10-digit NDCs. Many pharmacy and reimbursement systems convert them to an 11-digit 5-4-2 format for billing. FDA’s uniform 12-digit 6-4-2 NDC format takes effect March 7, 2033. FDA will continue assigning 10-digit NDCs through March 6, 2033.
Yes. The Labeler Code is the first NDC segment and must be in place before the product and package segments can be established and the drug listing completed. If you do not yet have a Labeler Code, FDA Registration Assistance can handle that filing first.
Typical information includes the legal labeler name, Labeler Code, product name, dosage form, route of administration, active and inactive ingredients, strengths, marketing category, manufacturing-establishment information, package configurations, and current product labeling.
Our professional service fee is $199 USD per drug product for NDC setup, SPL drug-listing preparation, FDA Direct submission support, and listing verification within the agreed scope. FDA does not charge a separate government fee simply to assign an NDC or submit a standard drug listing.
Drug registration and listing data are submitted electronically in Structured Product Labeling (SPL) format. FDA Direct, formerly CDER Direct for drug functions, is FDA’s free web-based SPL authoring and submission environment. Other compliant SPL tools may use FDA ESG NextGen for transmission.
FDA requires drug-listing information to be kept current. Changes should be submitted as soon as possible and, where periodic reporting is permitted, no later than the following June or December reporting period. If no listing information changed during the year, the required no-change certification is generally completed during October 1 through December 31.
Yes. Foreign firms can list drug products for U.S. commercial distribution. The correct setup depends on the company’s role; foreign drug establishments generally must maintain FDA establishment registration and designate a U.S. Agent in addition to meeting applicable drug-listing requirements.
The Labeler Code identifies the labeler and forms the first segment of the NDC. The complete NDC combines that Labeler Code with a product code and package code so a specific listed drug and commercial package can be identified.
Yes. Different commercial package configurations can require different package codes, producing different complete NDCs even when the underlying formulation and strength are the same. We review every package size and type before building the listing.
FDA’s National Drug Code Directory is updated daily from submitted drug-listing data. You can search by NDC, product name, or labeler. Directory inclusion reflects submitted listing information and should not be interpreted as FDA approval or a guarantee of reimbursement.
Send us your product and company details. We’ll review what is already in place, identify any prerequisite filing, and determine the correct NDC / SPL drug-listing path.
Prefer to speak with us? Call 928-275-8333 or email info@fdaregistrationassistance.com.
Your NDC / drug-listing inquiry was submitted successfully. Our team will review the information and contact you shortly.